Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Hironobu Goto, Taro Oshikiri, Takashi Kato, Yoshiaki Nagatani, Yohei Funakoshi, Yasufumi Koterazawa, Ryuichiro Sawada, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Hironobu Minami, Yoshihiro Kakeji
BACKGROUND: In Japan, preoperative adjuvant chemotherapy followed by surgical resection is the standard treatment for patients with locally advanced esophageal squamous cell carcinoma. However, the risk of recurrence after surgical resection remains high. Although a randomized controlled trial evaluating the efficacy of nivolumab, a fully human monoclonal anti-programmed death 1 antibody, as postoperative adjuvant therapy after neoadjuvant chemoradiotherapy and surgery established its superior efficacy as adjuvant therapy, the efficacy for patients who received preoperative adjuvant chemotherapy has not been demonstrated...
2024: PloS One
#22
JOURNAL ARTICLE
Sergi Fernandez-Gonzalez, Catalina Falo, Maria J Pla, Miriam Campos, Carlos Ortega-Exposito, Raul Ortega, Maria Vicente, Ana Petit, Jan Bosch-Schips, Maria Teresa Bajen, Gabriel Reyes, Evelyn Martínez, Javier González-Viguera, Judith Peñafiel, Agostina Stradella, Sonia Pernas, Jordi Ponce, Amparo Garcia-Tejedor
PURPOSE: In patients with clinically lymph node-negative (cN0) breast cancer, performing sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) has been preferentially embraced in comparison to before NACT. However, survival outcomes associated with both strategies remain understudied. We aimed to compare the axillary lymphadenectomy (ALND) rate, disease-free survival (DFS), and overall survival (OS), between two strategies. METHODS: We included 310 patients in a retrospective observational study...
April 18, 2024: Breast Cancer Research and Treatment
#23
JOURNAL ARTICLE
Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Umberto Basso, Marco Maruzzo, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin W Myint, Luca Galli, Vinicius Carrera Souza, Renate Pichler, Ugo De Giorgi, Nathalia Gandur, Elaine T Lam, Danielle Gilbert, Lazar Popovic, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J Crabb, Robert Kemp, Javier Molina-Cerrillo, Marcelo Freitas, Murilo Luz, Roberto Iacovelli, Fabio Calabrò, Deniz Tural, Francesco Atzori, Zsófia Küronya, Rita Chiari, Saul Campos, Orazio Caffo, André P Fay, Jakub Kucharz, Paolo Andrea Zucali, José Augusto Rinck, Annalisa Zeppellini, Diogo Assed Bastos, Gaetano Aurilio, Augusto Mota, Karine Trindade, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Allan Barillas, Fernando Sabino M Monteiro, Breno Dauster, Alessia Mennitto, Lucas Nogueira, Roni de Carvalho Fernandes, Emmanuel Seront, Luís Garcia Aceituno, Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernandez, Maria Bassanelli, Ray Manneh Kopp, Giandomenico Roviello, Halima Abahssain, Giuseppe Procopio, Michele Milella, Jindrich Kopecky, Angelo Martignetti, Carlo Messina, Manuel Caitano, Eva Inman, Ravindran Kanesvaran, Daniel Herchhorn, Daniele Santini, Aristotelis Bamias, Renato Bisonni, Alessandra Mosca, Franco Morelli, Fernando Maluf, Andrey Soares, Fernando Nunes, Alvaro Pinto, Anca Zgura, Lorena Incorvaia, Jawaher Ansari, Ignacio Ortego Zabalza, Johannes Landmesser, Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Matteo Rosellini, Giulia Sorgentoni, Nicola Battelli, Sebastiano Buti, Camillo Porta, Joaquim Bellmunt
BACKGROUND: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. PATIENTS AND METHODS: Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries...
April 18, 2024: Cancer Immunology, Immunotherapy: CII
#24
JOURNAL ARTICLE
María de Armas Conde, Carmen Díaz-López, Vanessa Concepción-Martín, María Del Pilar Borque-Barrera
BACKGROUND AND STUDY AIMS: Upper gastrointestinal tract (UGT) leaks are associated with severe morbidity and mortality. Endoluminal vacuum (EVAC) therapy is a promising approach for repairing effectively these defects. Our study describes the results obtained from a series of cases treated with EVAC for the management of esophageal anastomotic (EA) leak following esophagectomy for cancer, gastroenteric (GE) anastomoses leak after bariatric surgery and esophageal perforation (EP). PATIENTS AND METHODS: We retrospectively analyzed ten patients who had an EA and GE anastomoses leaks and EP treated with EVAC...
April 18, 2024: Revista Española de Enfermedades Digestivas
#25
JOURNAL ARTICLE
José María Rodríguez Lucas, Emilio Peña Ros, Francisco Miguel González Valverde
A 62 year-old-man with low anterior rectal resection and protective ileostomy, for low rectal neo and neoadjuvant QT +RT. Then ileostomy closure without incidences. On the 3rd postoperative day, he started with fever peaks and diarrhea. An abdominal CT scan showed diffuse thickening of the wall of the descending colon compatible with colitis and colonoscopy showed deep rectal ulcers with punch-like morphology with hyperemic mucosa with erythematous stippling of erosive appearance, showing this ulcerative pattern with numerous lesions and intensely edematous and congestive mucosa covered with abundant fibrinopurulent exudate in the descending colon...
April 18, 2024: Revista Española de Enfermedades Digestivas
#26
JOURNAL ARTICLE
Mohammed Al-Zubaidi, Katherine Ong, Pravin Viswambaram, Haider Bangash, Glenn Boardman, Steve P McCombie, Oliver Oey, Nicole Swarbrick, Andrew Redfern, Jeremy Ong, Richard Gauci, Ronny Low, Dickon Hayne
OBJECTIVES: We aim to assess the clinical value of 18 F-fluorodeoxyglucose positron (18 F-FDG-PET) scan in detecting nodal and distant metastasis compared with computed tomography (CT) scan in patients with urothelial carcinoma or bladder cancer, aiming to improve staging accuracy and thereby better prognosticate and determine therapy. METHODS: A retrospective review of 75 patients with invasive bladder cancer (≥T1) who were staged with both CT and 18 F-FDG-PET within an 8-week interval was performed for the period between 2015 and 2020...
April 2024: BJUI compass
#27
JOURNAL ARTICLE
C Sanghera, D P McClurg, C M Jones
BACKGROUND AND AIM: There has been limited progress made in improving the suboptimal outcomes delivered by conventionally fractionated radiotherapy (RT) for oesophageal adenocarcinoma (OAC) and squamous cell carcinoma (OSCC). A greater biological effect may be achieved using hypofractionated RT (HFRT), though the toxicity, tolerability and efficacy of this approach in OAC and OSCC is uncertain. METHODS: A systematic literature review was carried out in accordance with Preferred Reporting Items for Systematic Reviews guidance...
March 18, 2024: Clinical Oncology: a Journal of the Royal College of Radiologists
#28
REVIEW
Zhifan Li, Xinran Liu, Ya Gao, Xingru Lu, Junqiang Lei
OBJECTIVE: This study aims to evaluate the diagnostic accuracy of ultrasound imaging (US)-based radiomics for the early prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. METHODS: We comprehensively searched PubMed, Cochrane Library, Embase, and Web of Science databases up to 1 January 2023 for eligible studies. We assessed the methodological quality of the enrolled studies with Radiomics Quality Score (RQS) and the Quality Assessment of Diagnostic Accuracy Studies-2 tools...
April 17, 2024: La Radiologia Medica
#29
JOURNAL ARTICLE
Kamil Nurczyk, Norbert Nowak, Tomasz Orczykowski, Paweł Bojar, Dariusz Duma, Renata Gieroba, Grzegorz Wallner, Tomasz Skoczylas
<b><br>Introduction:</b> Neoadjuvant chemotherapy (NAC) is a part of the current standard of care in a locally advanced gastric adenocarcinoma (GA) and esophagogastric junction adenocarcinoma (EGJA), but only patients with good pathomorphological response (pR) to NAC benefit from prolonged overall survival.</br> <b><br>Aim:</b> The study aims to evaluate ApoA-I and ApoB as candidate pre-treatment biomarkers of pR to NAC in patients with GA and EGJA...
September 20, 2023: Polski Przeglad Chirurgiczny
#30
JOURNAL ARTICLE
Luise Rupp, Ina Dietsche, Maximilian Kießler, Ulrich Sommer, Alexander Muckenhuber, Katja Steiger, Casper W F van Eijck, Leonard Richter, Rouzanna Istvanffy, Carsten Jäger, Helmut Friess, Casper H J van Eijck, Ihsan Ekin Demir, Carmen Mota Reyes, Marc Schmitz
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at advanced stages and associated with early distant metastasis and poor survival. Besides clinical factors, the tumor microenvironment (TME) emerged as a crucial determinant of patient survival and therapy response in many tumors, including PDAC. Thus, the presence of tumor-infiltrating lymphocytes and the formation of tertiary lymphoid structures (TLS) is associated with longer survival in PDAC. Although neoadjuvant therapy (NeoTx) has improved the management of locally advanced tumors, detailed insight into its effect on various TME components is limited...
2024: Frontiers in Immunology
#31
JOURNAL ARTICLE
Melina Boutin, Tharani Krishnan, Maria Safro, Jenny Yang, Helia Jafari, Janine M Davies, Sharlene Gill
BACKGROUND: Complete resection followed by adjuvant chemotherapy is the gold standard for patients with localized cholangiocarcinoma (CC) or gallbladder cancer (GBC). However, this is not always feasible, and recurrence rates remain high. OBJECTIVES: To understand the real-world proportions and reason for treatment failure in resected biliary tract cancers. DESIGN AND METHODS: We performed a retrospective population-based review of patients with GBC or CC [intrahepatic (IHCC) or extrahepatic (EHCC)] resected between 2005 and 2019 using the BC Cancer provincial database...
2024: Therapeutic Advances in Medical Oncology
#32
JOURNAL ARTICLE
Betty Y Zhang, Ashley R Wilson-Smith, Elizabeth A Connolly, Madeleine C Strach, Nathan Ussher, Tristan Yan, Vivek A Bhadri
BACKGROUND: Extrapleural pneumonectomy (EPP) is a complex surgical procedure involving en-bloc resection of the parietal and visceral pleura, lung, pericardium, and ipsilateral diaphragm. Small case series of pleural-based sarcoma of predominantly pediatric patients suggest EPP may be a life-prolonging surgical option. We aimed to describe the characteristics and outcomes of adults who underwent EPP at a specialized sarcoma center. METHODS: Clinicopathologic variables, surgical details, and follow-up information were extracted for patients undergoing EPP for pleural-based sarcoma between August 2017 and December 2020...
April 2024: Cancer reports
#33
JOURNAL ARTICLE
Misbah Younus Soomro, Saqib Raza Khan, Hafiz Muhammad, Sujjawal Ahmad, Nawazish Zehra, Insia Ali, Mirza Rameez Samar, Arif Hameed, Munira Moosajee, Yasmin Abdul Rashid
BACKGROUND: Rectal cancer treatment has transformed in recent years, with neoadjuvant treatment (NT) and total neoadjuvant treatment (TNT) aiming to enhance pathological responses. This pioneering study in our country delves into rectal cancer management, offering crucial insights by examining pathological outcomes in patients treated with the NT and TNT approach, shaping the evolving landscape. METHODS: In this retrospective-cohort study spanning January 2017 to December 2022 at a tertiary care hospital in Pakistan, ethical approval was obtained to examine outcomes of two treatments...
April 16, 2024: BMC Cancer
#34
JOURNAL ARTICLE
Atilla Çelik, Fikret Çalıkoğlu, Ahmet Akbaş, Gülçin Ercan, Ali Muhammedoğlu
PURPOSE: Breast cancer is the most common cancer in women. Developments in breast cancer treatment have extended the life expectancy of these patients, raising the issue of morbidity of breast cancer surgery, the major cause of which is axillary dissection. The aim of the present study was to establish the safety of sentinel node biopsy (SLNB) in patients with a clinically node-negative axilla after neoadjuvant chemotherapy (NACT). METHODS: We recorded demographic data, as well as the findings of physical examination, imaging, and pathology before and after NACT...
April 16, 2024: Surgery Today
#35
JOURNAL ARTICLE
Manqi Zhang, Hailing Zha, Jiazhen Pan, Xiaoan Liu, Min Zong, Liwen Du, Yu Du
BACKGROUND: The accurate prediction of pathological complete response (pCR) in the breast and axillary lymph nodes (ALN) before neoadjuvant chemotherapy (NAC) is of utmost importance for the development of treatment strategies. We aim to construct a nomogram on ultrasound (US) and clinical-pathologic factors to predict breast and ALN pCR in node-positive triple-negative breast cancers (TNBCs). METHODS: Patients identified with TNBCs from institution 1 (n = 328) were used for training cohort and those from institution 2 (n = 192) were for validation cohort...
March 23, 2024: Clinical Breast Cancer
#36
JOURNAL ARTICLE
Jessica Donington, Xiaohan Hu, Su Zhang, Yan Song, Ashwini Arunachalam, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch, Ayman Samkari
BACKGROUND: Novel neoadjuvant chemoimmunotherapy treatments are being investigated for locally advanced non-small-cell lung cancer (NSCLC), but real-world outcomes for neoadjuvant treatments are poorly understood. This study examined neoadjuvant treatment patterns, real-world event-free survival (rwEFS) and overall survival (OS) in patients with resected, stage II-III NSCLC in the United States (US). METHODS: This retrospective study identified patients in the SEER-Medicare database (2007-2019) with newly diagnosed stage II, IIIA, and IIIB (N2) NSCLC (AJCC 8th edition) treated with neoadjuvant chemo/chemoradiotherapy and resection (index date: neoadjuvant therapy initiation)...
March 22, 2024: Clinical Lung Cancer
#37
JOURNAL ARTICLE
Tijs J Hoogteijling, Mohammad Abu Hilal, Giuseppe Zimmitti, Davit L Aghayan, Andrew G R Wu, Federica Cipriani, Salvatore Gruttadauria, Olivier Scatton, Tran Cong Duy Long, Paulo Herman, Marco V Marino, Vincenzo Mazzaferro, Adrian K H Chiow, Iswanto Sucandy, Arpad Ivanecz, Sung Hoon Choi, Jae Hoon Lee, Mikel Gastaca, Marco Vivarelli, Felice Giuliante, Andrea Ruzzenente, Chee Chien Yong, Mengqiu Yin, Constantino Fondevila, Mikhail Efanov, Zenichi Morise, Fabrizio Di Benedetto, Raffaele Brustia, Raffaele Dalla Valle, Ugo Boggi, David Geller, Andrea Belli, Riccardo Memeo, Alejandro Mejia, James O Park, Fernando Rotellar, Gi Hong Choi, Ricardo Robles-Campos, Xiaoying Wang, Robert P Sutcliffe, Johann Pratschke, Chung-Ngai Tang, Charing C N Chong, Mathieu D'Hondt, Kazuteru Monden, Santiago Lopez-Ben, T Peter Kingham, Alessandro Ferrero, Giuseppe Maria Ettorre, Daniel Cherqui, Xiao Liang, Olivier Soubrane, Go Wakabayashi, Roberto I Troisi, Ho Seong Han, Tan To Cheung, Atsushi Sugioka, Safi Dokmak, Kuo Hsin Chen, Rong Liu, David Fuks, Wanguang Zhang, Luca Aldrighetti, Bjørn Edwin, Brian K P Goh
BACKGROUND: In the last three decades, minimally invasive liver resection has been replacing conventional open approach in liver surgery. More recently, developments in neoadjuvant chemotherapy have led to increased multidisciplinary management of colorectal liver metastases with both medical and surgical treatment modalities. However, the impact of neoadjuvant chemotherapy on the surgical outcomes of minimally invasive liver resections remains poorly understood. METHODS: A multicenter, international, database of 4998 minimally invasive minor hepatectomy for colorectal liver metastases was used to compare surgical outcomes in patients who received neoadjuvant chemotherapy with surgery alone...
April 2, 2024: European Journal of Surgical Oncology
#38
JOURNAL ARTICLE
Giuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, Emilio Francesco Giunta, Akash Maniam, Shobana Anpalakhan, Shyamika Acharige, Aruni Ghose, Alfredo Addeo
IMPORTANCE: Randomized clinical trials (RCTs) with neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non-small cell lung cancer (NSCLC) have reported consistent associations with event-free survival (EFS) and pathologic complete response (pCR) pending longer follow-up for overall survival data. OBJECTIVE: To assess the pooled benefit of ICI-chemotherapy in 2-year EFS and pCR among patients with NSCLC and examine the impact of clinical, pathologic, and treatment-related factors...
April 1, 2024: JAMA Network Open
#39
JOURNAL ARTICLE
Saida Sakhri, Ons Krimi, Nayssem Khessairi, Fethia Abidi, Maher Slimane, Hanen Bouaziz, Tarek Ben Dhiab
INTRODUCTION: Infectious affections are the most frequent post-operative complications, the rate have been reducing due to the administration of perioperative antibiotics and they are rarely serious. They are usually associated to pelvic collections, fistulas, urinary tract stenosis and, exceptionally, necrotizing fasciitis (FN) and pelvic organ necrosis. There is no well-codified treatment. CASE PRESENTATION: A 42-year-old female patient, was referred to our department for a stage IIIC2 adenocarcinoma of the uterine cervix...
April 15, 2024: BMC Women's Health
#40
JOURNAL ARTICLE
Marta Sevieri, Francesco Andreata, Francesco Mainini, Lorena Signati, Francesca Piccotti, Marta Truffi, Arianna Bonizzi, Leopoldo Sitia, Claudia Pigliacelli, Carlo Morasso, Barbara Tagliaferri, Fabio Corsi, Serena Mazzucchelli
Despite the advent of numerous targeted therapies in clinical practice, anthracyclines, including doxorubicin (DOX), continue to play a pivotal role in breast cancer (BC) treatment. DOX directly disrupts DNA replication, demonstrating remarkable efficacy against BC cells. However, its non-specificity toward cancer cells leads to significant side effects, limiting its clinical utility. Interestingly, DOX can also enhance the antitumor immune response by promoting immunogenic cell death in BC cells, thereby facilitating the presentation of tumor antigens to the adaptive immune system...
April 15, 2024: Journal of Nanobiotechnology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
